Rapid adoption High patient throughput capability and quick 12-second setup position HemaClear as an attractive upgrade for surgical suites seeking faster turnover and reduced intraoperative delays.

Cost efficiency Sterile, single-use design eliminates reprocessing, lowers risk of cross-contamination, and reduces equipment footprints, offering hospitals a clear total cost of ownership advantage.

Exsanguination leadership Marketed as enabling a wide surgical field with minimal blood leakage, the device can be pitched to procurement teams as improving visibility and precision for orthopedics and related procedures.

Hospital traction Adoption by prominent hospitals and a broad customer base in major U.S. centers suggests a scalable path through existing multihospital systems and GPOs.

Growth opportunities Revenue signals indicate a viable sales target for adjacent orthopedic and vascular procedures, with potential upsell to larger medical device players or distributors seeking innovative tourniquet solutions.